Applied DNA Sciences Inc. (APDN)
Applied DNA Sciences Statistics
Share Statistics
Applied DNA Sciences has 1.1M shares outstanding. The number of shares has increased by 208% in one year.
Shares Outstanding | 1.1M |
Shares Change (YoY) | 208% |
Shares Change (QoQ) | 407.74% |
Owned by Institutions (%) | 0.08% |
Shares Floating | 1.03M |
Failed to Deliver (FTD) Shares | 6.76K |
FTD / Avg. Volume | 1.18% |
Short Selling Information
The latest short interest is 1.77M, so 3.21% of the outstanding shares have been sold short.
Short Interest | 1.77M |
Short % of Shares Out | 3.21% |
Short % of Float | 3.22% |
Short Ratio (days to cover) | 0.47 |
Valuation Ratios
The PE ratio is -18.43 and the forward PE ratio is -0.18. Applied DNA Sciences's PEG ratio is 0.21.
PE Ratio | -18.43 |
Forward PE | -0.18 |
PS Ratio | 37.55 |
Forward PS | 0.3 |
PB Ratio | 14.09 |
P/FCF Ratio | -9.13 |
PEG Ratio | 0.21 |
Enterprise Valuation
Applied DNA Sciences Inc. has an Enterprise Value (EV) of 310.51M.
EV / Earnings | -44.41 |
EV / Sales | 90.49 |
EV / EBITDA | -22.14 |
EV / EBIT | -22.14 |
EV / FCF | -21.99 |
Financial Position
The company has a current ratio of 3.36, with a Debt / Equity ratio of 0.08.
Current Ratio | 3.36 |
Quick Ratio | 3.17 |
Debt / Equity | 0.08 |
Total Debt / Capitalization | 7.48 |
Cash Flow / Debt | -18.55 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.76% and return on capital (ROIC) is -147.28%.
Return on Equity (ROE) | -0.76% |
Return on Assets (ROA) | -0.55% |
Return on Capital (ROIC) | -147.28% |
Revenue Per Employee | $74,596.09 |
Profits Per Employee | $-152,011.33 |
Employee Count | 46 |
Asset Turnover | 0.27 |
Inventory Turnover | 5.51 |
Taxes
Income Tax | 137.3K |
Effective Tax Rate | -0.02 |
Stock Price Statistics
The stock price has increased by -99.56% in the last 52 weeks. The beta is 0.42, so Applied DNA Sciences's price volatility has been higher than the market average.
Beta | 0.42 |
52-Week Price Change | -99.56% |
50-Day Moving Average | 7.23 |
200-Day Moving Average | 22.86 |
Relative Strength Index (RSI) | 23.69 |
Average Volume (20 Days) | 572.65K |
Income Statement
In the last 12 months, Applied DNA Sciences had revenue of 3.43M and earned -6.99M in profits. Earnings per share was -1.76.
Revenue | 3.43M |
Gross Profit | 1.02M |
Operating Income | -14.02M |
Net Income | -6.99M |
EBITDA | -14.02M |
EBIT | -14.02M |
Earnings Per Share (EPS) | -1.76 |
Balance Sheet
The company has 6.43M in cash and 739.16K in debt, giving a net cash position of 5.69M.
Cash & Cash Equivalents | 6.43M |
Total Debt | 739.16K |
Net Cash | 5.69M |
Retained Earnings | -309.67M |
Total Assets | 15.97M |
Working Capital | 8.89M |
Cash Flow
In the last 12 months, operating cash flow was -13.71M and capital expenditures -407.9K, giving a free cash flow of -14.12M.
Operating Cash Flow | -13.71M |
Capital Expenditures | -407.9K |
Free Cash Flow | -14.12M |
FCF Per Share | -3.56 |
Margins
Gross margin is 29.63%, with operating and profit margins of -408.72% and -203.78%.
Gross Margin | 29.63% |
Operating Margin | -408.72% |
Pretax Margin | -206.57% |
Profit Margin | -203.78% |
EBITDA Margin | -408.72% |
EBIT Margin | -408.72% |
FCF Margin | -411.47% |
Dividends & Yields
APDN does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -83.02% |
FCF Yield | -603.39% |
Analyst Forecast
The average price target for APDN is $75, which is 3437.7% higher than the current price. The consensus rating is "Buy".
Price Target | $75 |
Price Target Difference | 3437.7% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Mar 14, 2025. It was a backward split with a ratio of 1:50.
Last Split Date | Mar 14, 2025 |
Split Type | backward |
Split Ratio | 1:50 |
Scores
Altman Z-Score | -30.16 |
Piotroski F-Score | 3 |